African health sciences
-
African health sciences · Jun 2023
Alisma Shugan Decoction attenuates hepatic fibrosis and endoplasmic reticulum stress in mice with carbon tetrachloride-induced fibrosis.
Over the years, Alisma Shugan Decoction (ASD), because of its potent anti-inflammation activity, has been used in traditional Chinese medicine (TCM) for treatment of many inflammation-associated disorders including those of the heart, blood vessel and brain. ⋯ In conclusion, the present study provides preclinical evidence for the use of ASD as an efficacious therapeutic option in cases of chemical-induced liver damage and/or fibrosis. Further large-cohort validation of these findings is warranted.
-
African health sciences · Jun 2023
Factors influencing tuberculosis preventive practices among people living with HIV/AIDS enrolled in secondary health facilities in Lagos, Nigeria.
Tuberculosis is the most potent opportunistic infection leading to deaths among patients with Human Immunodeficiency Virus (HIV). Therefore, knowledge, attitude and practices regarding tuberculosis preventive strategy among People Living with HIV/AIDS (PLWHA) is vital in minimizing the risk of developing TB infection which forms the objective of this study. ⋯ Over half of respondents had good tuberculosis preventive practices, influenced by their socio-demographic characteristics, knowledge and attitude towards TB infection. Preventive efforts need to be strengthened among individuals between 18-27 years of age, non-Christians and those with lower educational status.
-
African health sciences · Jun 2023
Meta AnalysisTherapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
The efficacy of dapagliflozin remains controversial for patients with type 2 diabetes and non-alcoholic fatty liver disease. We conduct this meta-analysis to explore the influence of dapagliflozin versus placebo on the treatment efficacy of type 2 diabetes complicated with non-alcoholic fatty liver disease. ⋯ Dapagliflozin benefits to improve hepatic function and glucose control in patients with type 2 diabetes and non-alcoholic fatty liver disease, as evidenced by the reduction in ALT, AST, fasting glucose and HbA1c.